A Phase 2 interventional study of rLP2086 and rLP2086 in Healthy, sponsored by Pfizer. Completed at 9 sites in Australia. Open to participants aged 8 Years to 14 Years. Per ClinicalTrials.gov, last updated 2014-11-21.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to evaluate the safety of an investigational meningitis vaccine and the immune response to it in adolescents
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion Criteria
Exclusion Criteria:
Exclusion Criteria
20ug Experimental
Biological: rLP2086
60ug Experimental
Biological: rLP2086
200ug Experimental
Biological: rLP2086
Active comparator
Biological: rLP2086
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
Vaccine administered at 0, 1, and 6 months
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
Vaccine administered at 0, 1, and 6 months
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
Vaccine administered at 0, 1, and 6 months
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
Vaccine administered at 0, 1, and 6 months
Percentage of Participants With Seroconversion in rLP2086 Specific Serum Bactericidal Assay (SBA) Titer 1 Month After Dose 2
Time frame: 1 month after Dose 2
Percentage of Participants With Seroconversion in rLP2086 Specific SBA Titer 1 Month After Dose 3
Time frame: 1 month after Dose 3
Percentage of Participants With at Least One Adverse Event (AE)
Time frame: Dose 1 up to 1 month after Dose 3
| Milestone | Twinrix | Initial Formulation rLP2086 20 mcg | Initial Formulation rLP2086 60 mcg | Initial Formulation rLP2086 200 mcg |
|---|---|---|---|---|
| Started | 21 | 16 | 45 | 45 |
| Completed | 20 | 15 | 43 | 43 |
| Not completed | 1 | 1 | 2 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 |
| Withdrew: Parent/legal guardian request | 0 | 0 | 1 | 1 |
| percentage of participants | Twinrix | Initial Formulation rLP2086 20 mcg | Initial Formulation rLP2086 60 mcg | Initial Formulation rLP2086 200 mcg |
|---|---|---|---|---|
| PMB1745 (N=19, 15, 44, 42) | 0.0 (0.0 to 17.6) | 33.3 (11.8 to 61.6) | 63.6 (47.8 to 77.6) | 83.3 (68.6 to 93.0) |
| PMB17 (N=18, 16, 44, 42) | 0.0 (0.0 to 18.5) | 18.8 (4.0 to 45.6) | 52.3 (36.7 to 67.5) | 61.9 (45.6 to 76.4) |
| percentage of participants | Twinrix | Initial Formulation rLP2086 20 mcg | Initial Formulation rLP2086 60 mcg | Initial Formulation rLP2086 200 mcg |
|---|---|---|---|---|
| PMB1745 (N=19, 16, 41, 43) | 0.0 (0.0 to 17.6) | 68.8 (41.3 to 89.0) | 70.7 (54.5 to 83.9) | 90.7 (77.9 to 97.4) |
| PMB17 (N=18, 16, 41, 43) | 0.0 (0.0 to 18.5) | 87.5 (61.7 to 98.4) | 82.9 (67.9 to 92.8) | 95.3 (84.2 to 99.4) |
| percentage of participants | Twinrix | Initial Formulation rLP2086 20 mcg | Initial Formulation rLP2086 60 mcg | Initial Formulation rLP2086 200 mcg |
|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event (AE) | 90.5 | 93.8 | 93.3 | 97.8 |
Collected over Dose 1 up to 1 month after Dose 3. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Twinrix | — | 0/21 (0%) | 19/21 (90.5%) |
| Initial Formulation rLP2086 20 mcg | — | 2/16 (12.5%) | 15/16 (93.8%) |
| Initial Formulation rLP2086 60 mcg | — | 3/45 (6.7%) | 42/45 (93.3%) |
| Initial Formulation rLP2086 200 mcg | — | 3/45 (6.7%) | 44/45 (97.8%) |
| Event | Twinrix | Initial Formulation rLP2086 20 mcg | Initial Formulation rLP2086 60 mcg | Initial Formulation rLP2086 200 mcg |
|---|---|---|---|---|
| OrchitisInfections and infestations | 0/21 | 1/16 | 0/45 | 0/45 |
| ContusionInjury, poisoning and procedural complications | 0/21 | 1/16 | 0/45 | 0/45 |
| AppendicitisInfections and infestations | 0/21 | 0/16 | 2/45 | 0/45 |
| Abdominal painGastrointestinal disorders | 0/21 | 0/16 | 0/45 | 1/45 |
| Injection site erythemaGeneral disorders | 0/21 | 0/16 | 0/45 | 1/45 |
| Injection site painGeneral disorders | 0/21 | 0/16 | 0/45 | 1/45 |
| Injection site swellingGeneral disorders | 0/21 | 0/16 | 0/45 | 1/45 |
| Foot fractureInjury, poisoning and procedural complications | 0/21 | 0/16 | 1/45 | 0/45 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/21 | 0/16 | 0/45 | 1/45 |
| Event | Twinrix | Initial Formulation rLP2086 20 mcg | Initial Formulation rLP2086 60 mcg | Initial Formulation rLP2086 200 mcg |
|---|---|---|---|---|
| HeadacheNervous system disorders | 12/21 | 4/16 | 18/45 | 23/45 |
| Upper respiratory tract infectionInfections and infestations | 11/21 | 5/16 | 25/45 | 23/45 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 5/21 | 0/16 | 10/45 | 5/45 |
| Abdominal painGastrointestinal disorders | 3/21 | 3/16 | 5/45 | 7/45 |
| SunburnInjury, poisoning and procedural complications | 2/21 | 3/16 | 1/45 | 1/45 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/21 | 3/16 | 2/45 | 1/45 |
| NauseaGastrointestinal disorders | 0/21 | 1/16 | 8/45 | 1/45 |
| VomitingGastrointestinal disorders | 3/21 | 2/16 | 3/45 | 3/45 |
| InfluenzaInfections and infestations | 2/21 | 2/16 | 6/45 | 4/45 |
| Viral infectionInfections and infestations | 0/21 | 0/16 | 5/45 | 6/45 |
| Age, Continuous(years) | Twinrix | Initial Formulation rLP2086 20 mcg | Initial Formulation rLP2086 60 mcg | Initial Formulation rLP2086 200 mcg | Total |
|---|---|---|---|---|---|
| Mean | 10.19 ± 1.44 | 10.69 ± 0.95 | 10.31 ± 1.24 | 10.31 ± 1.29 | 10.34 ± 1.25 |
| Sex: Female, Male(Participants) | Twinrix | Initial Formulation rLP2086 20 mcg | Initial Formulation rLP2086 60 mcg | Initial Formulation rLP2086 200 mcg | Total |
|---|---|---|---|---|---|
| Female | 10 | 9 | 22 | 28 | 69 |
| Male | 11 | 7 | 23 | 17 | 58 |
The record gives a start of Nov 2006, a primary completion of Jan 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine